EP2054384A4 - Promédicaments hydrosolubles chargés positivement contenant des acides aryl- et hétéroarylpropioniques et dotés d'une très grande vitesse de pénétration cutanée - Google Patents

Promédicaments hydrosolubles chargés positivement contenant des acides aryl- et hétéroarylpropioniques et dotés d'une très grande vitesse de pénétration cutanée

Info

Publication number
EP2054384A4
EP2054384A4 EP06795662A EP06795662A EP2054384A4 EP 2054384 A4 EP2054384 A4 EP 2054384A4 EP 06795662 A EP06795662 A EP 06795662A EP 06795662 A EP06795662 A EP 06795662A EP 2054384 A4 EP2054384 A4 EP 2054384A4
Authority
EP
European Patent Office
Prior art keywords
aryl
positively charged
skin penetration
penetration rate
charged water
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
EP06795662A
Other languages
German (de)
English (en)
Other versions
EP2054384A1 (fr
Inventor
Chongxi Yu
Lina Xu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
YU, CHONGXI
Techfields Biochem Co Ltd
Original Assignee
Techfields Biochem Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Techfields Biochem Co Ltd filed Critical Techfields Biochem Co Ltd
Publication of EP2054384A1 publication Critical patent/EP2054384A1/fr
Publication of EP2054384A4 publication Critical patent/EP2054384A4/fr
Pending legal-status Critical Current

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D333/00Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/06Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached to the ring carbon atoms
    • C07D333/22Radicals substituted by doubly bound hetero atoms, or by two hetero atoms other than halogen singly bound to the same carbon atom
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/02Stomatological preparations, e.g. drugs for caries, aphtae, periodontitis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00Drugs for disorders of the respiratory system
    • A61P11/06Antiasthmatics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00Drugs for genital or sexual disorders; Contraceptives
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00Drugs for dermatological disorders
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/02Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00Drugs for skeletal disorders
    • A61P19/08Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/02Drugs for disorders of the nervous system for peripheral neuropathies
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/04Centrally acting analgesics, e.g. opioids
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00Drugs for disorders of the nervous system
    • A61P25/06Antimigraine agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/02Ophthalmic agents
    • A61P27/06Antiglaucoma agents or miotics
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00Drugs for disorders of the senses
    • A61P27/16Otologicals
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D209/00Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/04Indoles; Hydrogenated indoles
    • C07D209/08Indoles; Hydrogenated indoles with only hydrogen atoms or radicals containing only hydrogen and carbon atoms, directly attached to carbon atoms of the hetero ring
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D209/00Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/02Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom condensed with one carbocyclic ring
    • C07D209/44Iso-indoles; Hydrogenated iso-indoles
    • C07D209/46Iso-indoles; Hydrogenated iso-indoles with an oxygen atom in position 1
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D209/00Heterocyclic compounds containing five-membered rings, condensed with other rings, with one nitrogen atom as the only ring hetero atom
    • C07D209/56Ring systems containing three or more rings
    • C07D209/80[b, c]- or [b, d]-condensed
    • C07D209/82Carbazoles; Hydrogenated carbazoles
    • C07D209/88Carbazoles; Hydrogenated carbazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to carbon atoms of the ring system
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D263/00Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/52Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings condensed with carbocyclic rings or ring systems
    • C07D263/54Benzoxazoles; Hydrogenated benzoxazoles
    • C07D263/56Benzoxazoles; Hydrogenated benzoxazoles with only hydrogen atoms, hydrocarbon or substituted hydrocarbon radicals, directly attached in position 2
    • C07D263/57Aryl or substituted aryl radicals
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D333/00Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
    • C07D333/02Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings
    • C07D333/04Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom
    • C07D333/26Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom not condensed with other rings not substituted on the ring sulphur atom with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D333/30Hetero atoms other than halogen
    • C07D333/32Oxygen atoms
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D491/00Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
    • C07D491/02Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
    • C07D491/04Ortho-condensed systems

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Ophthalmology & Optometry (AREA)
  • Neurosurgery (AREA)
  • Rheumatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Pulmonology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hospice & Palliative Care (AREA)
  • Reproductive Health (AREA)
  • Endocrinology (AREA)
  • Otolaryngology (AREA)
  • Immunology (AREA)
  • Dermatology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Indole Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Heterocyclic Compounds Containing Sulfur Atoms (AREA)
  • Furan Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Pyrrole Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
EP06795662A 2006-08-15 2006-08-15 Promédicaments hydrosolubles chargés positivement contenant des acides aryl- et hétéroarylpropioniques et dotés d'une très grande vitesse de pénétration cutanée Pending EP2054384A4 (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
PCT/IB2006/052815 WO2008020270A1 (fr) 2006-08-15 2006-08-15 Promédicaments hydrosolubles chargés positivement contenant des acides aryl- et hétéroarylpropioniques et dotés d'une très grande vitesse de pénétration cutanée

Publications (2)

Publication Number Publication Date
EP2054384A1 EP2054384A1 (fr) 2009-05-06
EP2054384A4 true EP2054384A4 (fr) 2010-11-03

Family

ID=39081992

Family Applications (1)

Application Number Title Priority Date Filing Date
EP06795662A Pending EP2054384A4 (fr) 2006-08-15 2006-08-15 Promédicaments hydrosolubles chargés positivement contenant des acides aryl- et hétéroarylpropioniques et dotés d'une très grande vitesse de pénétration cutanée

Country Status (7)

Country Link
EP (1) EP2054384A4 (fr)
JP (1) JP5424880B2 (fr)
CN (1) CN101506161B (fr)
AU (1) AU2006347391B2 (fr)
CA (1) CA2660814C (fr)
HK (1) HK1137425A1 (fr)
WO (1) WO2008020270A1 (fr)

Families Citing this family (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20090221703A1 (en) 2006-07-09 2009-09-03 Chongxi Yu High penetration composition and uses thereof
US20090238763A1 (en) 2006-07-09 2009-09-24 Chongxi Yu High penetration compositions and uses thereof
CN101489985B (zh) * 2006-07-18 2014-01-08 天津昕晨泰飞尔医药科技有限公司 具有快速皮肤穿透率的带正电荷的水溶性布洛芬前药
EP2084124B9 (fr) 2006-10-02 2015-07-01 Techfields Biochem Co. Ltd Promédicaments hydrosolubles de prostaglandines et composés analogues, positivement chargés, à taux de pénétration cutanée très élevé
CN101541743A (zh) 2006-11-08 2009-09-23 于崇曦 多肽及相关化合物的透皮给药系统
EP2656879B1 (fr) 2006-12-10 2017-06-28 Chongxi Yu Systèmes d'administration transdermique d'antibiotiques de beta-lactame
PL2125697T3 (pl) 2007-01-15 2017-01-31 Yu Dodatnio naładowane, rozpuszczalne w wodzie proleki retinoidów i związków podobnych do retinoidów o bardzo wysokich współczynnikach przenikania przez skórę
JP5389668B2 (ja) 2007-01-31 2014-01-15 チョンシー ユー 皮膚浸透率の非常に高い1H−イミダゾ[4,5−c]キノリン−4−アミン及び関連化合物の正に荷電した水溶性プロドラッグ
KR20190091378A (ko) * 2007-06-04 2019-08-05 테크필즈 인크 매우 높은 피부 및 막 침투율을 가지는 비스테로이드성 소염제(nsaia) 약물전구체 및 이들의 새로운 의약적 용도
KR20210123406A (ko) 2008-12-04 2021-10-13 충시 위 고투과력을 가진 조성물 및 이의 적용
PL2427475T3 (pl) 2009-05-08 2021-07-19 Techfields Biochem Co., Ltd. Kompozycje proleku o wysokim przenikaniu peptydów i związków powiązanych z peptydami
US9969751B2 (en) 2009-06-10 2018-05-15 Techfields Pharma Co., Ltd. High penetration prodrug compositions of antimicrobials and antimicrobial-related compounds
KR102443057B1 (ko) 2012-01-18 2022-09-14 테크필즈 파마 코., 엘티디. 폐 병태의 치료를 위한 고침투 전구약물 조성물 및 그의 약제학적 조성물
WO2014139161A1 (fr) 2013-03-15 2014-09-18 Techfields Pharma Co., Ltd. Nouveaux médicaments à pénétration élevée et leurs compositions pour le traitement de maladies de parkinson
JP5940036B2 (ja) * 2013-10-08 2016-06-29 テックフィールズ バイオケム カンパニー リミテッド 非常に速い皮膚透過率を有するアリール−及びヘテロアリールプロピオン酸の正荷電水溶性プロドラッグ
EP3215141A4 (fr) 2014-11-05 2018-06-06 Flexus Biosciences, Inc. Agents immunorégulateurs
US20160168108A1 (en) 2014-12-16 2016-06-16 Adt Pharmaceuticals, Inc. Method of treating or preventing ras-mediated diseases
US9862698B2 (en) 2014-12-16 2018-01-09 Adt Pharmaceuticals, Inc. Indenyl compounds, pharmaceutical compositions, and medical uses thereof
JP6290947B2 (ja) * 2016-02-05 2018-03-07 テックフィールズ バイオケム カンパニー リミテッド 非常に速い皮膚透過率を有するアリール−及びヘテロアリールプロピオン酸の正荷電水溶性プロドラッグ
US11186596B2 (en) 2018-04-26 2021-11-30 Adt Pharmaceuticals, Llc Anticancer indenes, indanes, azaindenes, azaindanes, pharmaceutical compositions and uses
WO2022052936A1 (fr) * 2020-09-09 2022-03-17 南京海融医药科技股份有限公司 Dérivé d'acide arylpropionique, composition pharmaceutique, procédé de préparation correspondant et utilisation associée
CN117916219A (zh) * 2021-07-06 2024-04-19 石家庄迪斯凯威医药科技有限公司 一类抗膀胱癌的季胺盐化合物及其应用
WO2023046078A1 (fr) * 2021-09-24 2023-03-30 石家庄迪斯凯威医药科技有限公司 Nouveau dérivé de pranoprofène, composition pharmaceutique et leur utilisation

Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1377316A (en) * 1972-06-27 1974-12-11 Syntex Corp Dialkylaminoalkyl esters of arylaliphatic acids and acid addition salts thereof
US3896145A (en) * 1972-07-24 1975-07-22 Hoffmann La Roche Carbazoles
GB1573322A (en) * 1975-12-24 1980-08-20 Hisamitsu Pharmaceutical Co Phenylactic acid ester derivatives
JPS58126846A (ja) * 1982-01-22 1983-07-28 Kaken Pharmaceut Co Ltd プロピオン酸アミノアルキルエステル誘導体、その製法およびそれを有効成分とする消炎、鎮痛剤

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
FR1593024A (fr) * 1968-09-18 1970-05-25
ZA738203B (en) * 1972-10-24 1975-05-28 Janssen Pharmaceutica Nv Aroyl-substituted phenylacetic acid derivatives
IT1090782B (it) * 1977-11-30 1985-06-26 Menarini Sas 2 4 bifenilil 2 dietilamino alchil propionamide suoi sali e procedimenti di fabbricazione relativi
JPS6452742A (en) * 1987-04-27 1989-02-28 Syntex Pharma Int Omega-quaternary ammonium alkyl ester and thioester of acidic non-steroidal antiinflammatory
IT1317826B1 (it) * 2000-02-11 2003-07-15 Dompe Spa Ammidi, utili nell'inibizione della chemiotassi dei neutrofiliindotta da il-8.
ITMI20010395A1 (it) * 2001-02-27 2002-08-27 Dompe Spa Omega-amminoalchilammidi di acidi r-2-aril-propionici come inibitori della chemiotassi di cellule polimorfonucleate e mononucleate
ITMI20012025A1 (it) * 2001-09-28 2003-03-28 Dompe Spa Sali di ammonio quaternari di omega-amminoalchilammidi di acidi r 2-aril-propionici e composizioni farmaceutiche che li contengono

Patent Citations (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB1377316A (en) * 1972-06-27 1974-12-11 Syntex Corp Dialkylaminoalkyl esters of arylaliphatic acids and acid addition salts thereof
US3896145A (en) * 1972-07-24 1975-07-22 Hoffmann La Roche Carbazoles
GB1573322A (en) * 1975-12-24 1980-08-20 Hisamitsu Pharmaceutical Co Phenylactic acid ester derivatives
JPS58126846A (ja) * 1982-01-22 1983-07-28 Kaken Pharmaceut Co Ltd プロピオン酸アミノアルキルエステル誘導体、その製法およびそれを有効成分とする消炎、鎮痛剤

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
JARKKO RAUTIO ET AL: "Piperazinylalkyl prodrugs of naproxen improve in vitro skin permeation", EUROPEAN JOURNAL OF PHARMACEUTICAL SCIENCES, vol. 11, no. 2, 1 August 2000 (2000-08-01), pages 157 - 163, XP055049945, ISSN: 0928-0987, DOI: 10.1016/S0928-0987(00)00090-7 *
KAGAKU: "JPS58126846A -PROPIONIC ACID AMINOALKYL ESTER DERIVATIVE, ITS PREPARATION AND ANTIPHLOGISTIC AND ANALGESIC AGENT CONTAINING SAID DERIVATIVE AS ACTIVE COMPONENT", 28 July 1983 (1983-07-28), XP055442267, Retrieved from the Internet <URL:file:///C:/Users/MH52034/Desktop/JPS58126846%20translation.pdf> [retrieved on 20180118] *
No further relevant documents disclosed *
See also references of WO2008020270A1 *
SHANBHAG V R: "ESTER AND AMIDE PRODRUGS OF IBUPROFEN AND NAPROXEN: SYNTHESIS, ANTI-INFLAMMATORY ACTIVITY, AND GASTROINTESTINAL TOXICITY", JOURNAL OF PHARMACEUTICAL SCIENCES, AMERICAN PHARMACEUTICAL ASSOCIATION, WASHINGTON, US, vol. 81, no. 2, 1 February 1992 (1992-02-01), pages 149 - 154, XP000248778, ISSN: 0022-3549, DOI: 10.1002/JPS.2600810210 *

Also Published As

Publication number Publication date
AU2006347391B2 (en) 2013-03-07
CA2660814A1 (fr) 2008-02-21
JP2010500989A (ja) 2010-01-14
CN101506161A (zh) 2009-08-12
JP5424880B2 (ja) 2014-02-26
HK1137425A1 (en) 2010-07-30
CN101506161B (zh) 2013-11-13
EP2054384A1 (fr) 2009-05-06
CA2660814C (fr) 2017-07-18
WO2008020270A1 (fr) 2008-02-21
AU2006347391A1 (en) 2008-02-21

Similar Documents

Publication Publication Date Title
HK1137425A1 (en) Positively charged water-soluble prodrugs of aryl- and heteroarylpropionic acids with very fast skin penetration rate
PT2049482E (pt) Profármacos solúveis em água carregados positivamente de ácidos aril- e heteroarilacéticos com velocidade de penetração na pele muito rápida
HK1215805A1 (zh) 具有快速皮膚穿透速度的帶正電荷的水溶性雙氯芬酸前藥
HK1137426A1 (en) Positively charged water-soluble prodrugs of n-arylanthranilic acids with very fast skin penetration rate
HK1135958A1 (en) Positively charged water-soluble prodrugs of ibuprofen with very fast skin penetration rate
EP2061749A4 (fr) Promédicaments hydrosolubles positivement chargés d&#39;acétaminophène et de composés associés à vitesse de pénétration cutanée très élevée
HK1202524A1 (en) Positively charged water-soluble prodrugs of prostaglandins and related compounds with very high skin penetration rates
HK1136814A1 (en) Positively charged water-soluble prodrugs of diflunisal and related compounds with very fast skin penetration rate
PT2125697T (pt) Pró-fármacos solúveis em água positivamente carregados de retinóides e compostos tipo retinóide com taxas de penetração na pele muito altas
EP2084165A4 (fr) Pro-médicaments d&#39;oxicams solubles dans l&#39;eau et chargés positivement et composés apparentés avec une vitesse de pénétration de la peau très élevée
HK1243596A1 (zh) 作為鋅螯合劑的薑黃素類似物和其用途
IL217370A (en) New nucleic acid matrices and methods for using them
EP2288365A4 (fr) Facteurs de coagulation ciblés et procédés d&#39;utilisation de ceux-ci
HK1216096A1 (zh) 具有快速皮膚穿透速度的帶正電荷的水溶性的芥子類化合物及其相關化合物的前藥
IL223180A0 (en) Agomelatine intermediates and preparation method thereof
HK1208184A1 (en) Positively charged water-soluble prodrugs of ketoprofen and related compounds with very fast skin penetration rate
HK1208214A1 (en) Positively charged water-soluble prodrugs of ketoprofen and related compounds with very fast skin penetration rate
HK1202115A1 (en) Positively charged water-soluble prodrugs of oxicams and related compounds with very high skin penetration rate
HK1200031A1 (en) Positively charged water-soluble prodrugs of oxicams and related compounds with very high skin penetration rate
HK1196824A1 (zh) 具有快速皮膚穿透速度的帶正電荷的芳基和雜芳基乙酸類前藥

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20090220

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI SK TR

AX Request for extension of the european patent

Extension state: AL BA HR MK RS

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: YU, CHONGXI

Owner name: TECHFIELDS BIOCHEM CO. LTD

A4 Supplementary search report drawn up and despatched

Effective date: 20100930

DAX Request for extension of the european patent (deleted)
17Q First examination report despatched

Effective date: 20130816

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

RAP1 Party data changed (applicant data changed or rights of an application transferred)

Owner name: YU, CHONGXI

Owner name: TECHFIELDS BIOCHEM CO. LTD

PUAJ Public notification under rule 129 epc

Free format text: ORIGINAL CODE: 0009425

32PN Public notification

Free format text: NOTING OF LOSS OF RIGHTS PURSUANT TO EULE 112(1) EPC (EPO FORM 2561 DATED 17.02.2020)

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20191030

STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: EXAMINATION IS IN PROGRESS

D18D Application deemed to be withdrawn (deleted)
P01 Opt-out of the competence of the unified patent court (upc) registered

Effective date: 20230619